Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
A case report describes the first known link between anti-Homer3 antibody-positive autoimmune cerebellar ataxia and diffuse ...
Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...
InvestorsHub on MSN
Why is Artiva Biotherapeutics discontinuing AlloNK development and cutting 94% of its workforce?
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced on October 27, 2026, that it will discontinue development of its AlloNK ...
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
The case study demonstrates a durable complete response in a heavily pretreated DLBCL patient after a single administration ...
Minnesota Vikings wide receiver Justin Jefferson has raised more than $45,000 for cancer research through a charity bowling ...
Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and ...
Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trialUpdated deep B cell ...
TG Therapeutics reported early Phase 1 data for azer-cel in progressive multiple sclerosis and presented extensive long term ...
Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results